Alexandra Le Coz Sanchez
Associate Director, Private Equity Department, Debiopharm Investment S.A. @ Debiopharm Group
Alexandra Le Coz Sanchez is a Series A investor at Debiopharm Group focused on Software and Mobile Devices. Mrs Le Coz Sanchez obtained in 1998 a master II degree from the University of Paris-La Sorbonne: DESS "Information and Decision Techniques in the Enterprise". She has completed her education by participating in the CFA program and she successfully passed the level 3 exam in 2009. Alexandra has previously worked in different leadingmultinational companies where she was responsible for Planning, Forecasting and Budgeting with a strong focus on Marketing/Innovation and Supply Chain activities. She joined Debiomanagement (today Debiopharm Investment) in May 2010 as Financial Analyst.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Alexandra Le Coz Sanchez invests in
Stages Alexandra Le Coz Sanchez invests in
Countries Alexandra Le Coz Sanchez invests in
Investment Focus
Industry
- Software 1 (100%)
- Mobile Devices 1 (100%)
- Facial Recognition 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
KeyLemon
|
Gilles Florey and Yann Rodriguez founded KeyLemon in 2008 in Martigny (Switzerland), a region as renowned for its Alpine skiing and scenic beauty as for its entrepreneurial dynamism. They founded KeyLemon on the simple idea that your device should be able to recognize you in a natural and passive way as a human does. rather than you having toconstantly re-enter (and remember) a device password. Pioneering biometric authentication solutions via 2D and 3D face recognition for nearly ten years, KeyLemon has continuously pursued its vision for convenient security through effortless user recognition. Over the past decade, the technology company has remained true to this focus.KeyLemon offers biometric authentication solutions that are cutting edge, convenient, secure and continuous. The company’s flagship mobile product, Oasis, makes mobile authentication through face recognition as simple as taking a selfie. The unique client-server and client-only mobile solution has gained traction with developers and manufacturers across industries. In all its solutions, the company strives to improve secure access to high-value transaction services like banking or payment, regardless of device, system or application.KeyLemon remains headquartered in Switzerland, and the company has grown to serve clients across the globe. | $1.5M / Series A / Sep 02, 2013 |
Co-Investors
About Debiopharm Group
Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. They develop their products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.
Debiopharm Group Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Thierry Mauvernay
President & Delegate of the Board
|
|||
|
Alexandra Le Coz Sanchez
Associate Director, Private Equity Department, Debiopharm Investment S.A.
|
|||
ANGELA ZUBEL
Chief Development Officer
|
|||
Bertrand Ducrey
CEO
|
|||
Raymond Zaugg
Director, Financial department, Debiopharm Investment S.A
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alexandra Le Coz Sanchez invest in?
Alexandra Le Coz Sanchez invests primarily in Software, Mobile Devices and Facial Recognition startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alexandra Le Coz Sanchez last invest?
The most recent investment recorded for Alexandra Le Coz Sanchez closed in Sep 2013. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
